Quantification of Plasma Niraparib Using High‐Performance Liquid Chromatography in Patients With Ovarian Cancer
Biomedical Chromatography · 2025
DOI: 10.1002/bmc.70046 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomedical Chromatography, 2025. Verfasst von Yoshito Gando und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Therapy Research, Education and Research Unit for Comprehensive Clinical Pharmacy, Meiji Pharmaceutical University, Tokyo, Ja…. Hauptthemen laut MEDLINE: Indazoles, Ovarian Neoplasms, Piperidines, Poly(ADP-ribose) Polymerase Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: Nagai Memorial Research Scholarship from the Pharmaceutical Society of Japan.
Abstract (Originalsprache)
Niraparib is a small‐molecule inhibitor of poly(adenosine diphosphate [ADP]‐ribose) polymerase 1/2, which is used to treat ovarian cancer. Elevated maximum blood concentrations of niraparib and the area under the blood concentration–time curve (AUC) were correlated with body weight up to 77 kg. Lower body weight increases blood niraparib concentrations and the AUC of ovarian cancer in Asian patients. Therefore, therapeutic drug monitoring (TDM) of ovarian cancer drugs may increase niraparib efficacy and minimize adverse events. In this study, we quantified niraparib in human plasma (50 μL) using a simple and specific HPLC–UV method. The analyte was separated on a reversed‐phase column with an isocratic mobile phase of 0.5% KH 2 PO 4 (pH 4.5) and acetonitrile (75:25, v/v) at a flow rate of 1.0 mL/min. Calibration curves were linear over 0.25–5 μg/mL ( r 2 = 0.9998). Intraday and interday precision ranged from 2.25% to 6.29% and 1.73% to 3.20%, respectively, whereas accuracy and recovery ranged from −6.02% to −1.75% and > 93.2%, respectively. We cost‐effectively quantified steady‐state niraparib concentrations in the plasma of patients with ovarian cancer. Therefore, our method could be applied to the departments of pharmacy and clinical laboratories in general hospitals to facilitate the TDM of niraparib without the need for LC–MS/MS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicinal Therapy Research, Education and Research Unit for Comprehensive Clinical Pharmacy, Meiji Pharmaceutical University, Tokyo, Japan.
- Department of Pharmacy, Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan.
- Bokutoh Hospital-Meiji Pharmaceutical University Joint Research Center, Tokyo, Japan.
- Department of Clinical Laboratory, Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan.
- Department of Obstetrics and Gynecology, Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan.
ORCID-Profile: Yoshito Gando, Takeo Yasu
Förderung
- Nagai Memorial Research Scholarship from the Pharmaceutical Society of Japan
Zitieren
APA
Gando, Y., Hoshino, M., Ikuta, R., Shirota, M., Iwase, H., & Yasu, T. (2025). Quantification of Plasma Niraparib Using High‐Performance Liquid Chromatography in Patients With Ovarian Cancer. Biomedical Chromatography. https://doi.org/10.1002/bmc.70046
Vancouver
Gando Y, Hoshino M, Ikuta R, Shirota M, Iwase H, Yasu T. Quantification of Plasma Niraparib Using High‐Performance Liquid Chromatography in Patients With Ovarian Cancer. Biomedical Chromatography. 2025. doi:10.1002/bmc.70046
BibTeX
@article{Gando2025,
author = {Gando, Yoshito and Hoshino, Makoto and Ikuta, Risa and Shirota, Mikio and Iwase, Haruko and Yasu, Takeo},
title = {Quantification of Plasma Niraparib Using High‐Performance Liquid Chromatography in Patients With Ovarian Cancer},
journal = {Biomedical Chromatography},
year = {2025},
doi = {10.1002/bmc.70046}
}
EUVIMED